A

Armata Pharmaceuticals Inc
AMEX:ARMP

Watchlist Manager
Armata Pharmaceuticals Inc
AMEX:ARMP
Watchlist
Price: 5.9 USD 2.25% Market Closed
Market Cap: 214.3m USD

ARMP's latest stock split occurred on May 10, 2019

The company executed a 1-for-14 stock split, meaning that for every 14 shares held, investors received 1 new share.

Before the split, ARMP traded at 0.32 per share. Afterward, the share price was about 4.14.

The adjusted shares began trading on May 10, 2019. This was ARMP's 4th stock split, following the previous one in Apr 25, 2017.

Last Splits:
May 10, 2019
1-for-14
Apr 25, 2017
1-for-10
Aug 7, 2015
1-for-50
May 11, 2006
1-for-10
Pre-Split Price
4.48 0.32
Post-Split Price
4.14
Before
After
Last Splits:
May 10, 2019
1-for-14
Apr 25, 2017
1-for-10
Aug 7, 2015
1-for-50
May 11, 2006
1-for-10

Armata Pharmaceuticals Inc
Stock Splits History

ARMP Stock Splits Timeline
May 10, 2019
May 10, 2019
Split 1-for-14
/0.071428571428571
Pre-Split Price
4.48 0.32
Post-Split Price
4.14
Before
After
Apr 25, 2017
Apr 25, 2017
Split 1-for-10
/0.1
Pre-Split Price
49 0.35
Post-Split Price
45.5
Before
After
Aug 7, 2015
Aug 7, 2015
Split 1-for-50
/0.02
Pre-Split Price
1 400 0.2
Post-Split Price
1 400
Before
After
May 11, 2006
May 11, 2006
Split 1-for-10
/0.1
Pre-Split Price
23 100 0.33
Post-Split Price
22 750
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Dec 29, 2025
Ise Chemicals Corp
OTC:ICHMF
10-for-1
x10
32.808 32.808 USD N/A
Dec 29, 2025
Bridgestone Corp
OTC:BRDCF
2-for-1
x2
45.74 45.74 USD N/A
Dec 29, 2025
Ibiden Co Ltd
OTC:IBIDF
2-for-1
x2
81 81 USD N/A
Dec 29, 2025
Itochu Corp
OTC:ITOCF
5-for-1
x5
60.94 60.94 USD N/A
Dec 29, 2025
Sumitomo Realty & Development Co Ltd
OTC:SURDF
2-for-1
x2
50.55 50.55 USD N/A
Load More

Armata Pharmaceuticals Inc
Glance View

Market Cap
213.5m USD
Industry
Biotechnology

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company is headquartered in Marina Del Rey, California and currently employs 72 full-time employees. The firm is focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. The company has developed care therapies, including the multidrug-resistant or superbug strains of bacteria. The firm is a developer of phage therapeutics, which are positioned to address the growing worldwide threat of antibiotic-resistant bacterial infections. The company is developing and advancing its lead clinical phage candidate for Pseudomonas aeruginosa. The firm is also developing a phage product candidate for Staphylococcus aureus for the treatment of staphylococcus aureus bacteremia. The company has phage development to target other indications, including non-cystic fibrosis bronchiectasis, prosthetic joint infections and hospitalized pneumonia. Its product candidates are AP-PA02, AP-PA03 and AP-SA02.

ARMP Intrinsic Value
2.82 USD
Overvaluation 52%
Intrinsic Value
Price
A
Back to Top